Partner

Hannah Curtis

Languages

English

Social media

Hannah is a Partner in the Technology & Media team and a key member of the firm’s Lifesciences & Healthcare Sector Group. Hannah advises across sectors with a strong focus on life science and healthcare, supported by her background in biological sciences, where she acts for a range of biotech, speciality pharma, medical device and medical technology companies.

With nearly twenty years’ legal experience, she specialises high value, cross-border, IP-rich transactions and commercial agreements, including licensing, R&D, manufacturing, sales and distribution, collaborations, alliances and joint ventures. During her time with the firm, Hannah has been seconded to the Wellcome Trust, Pfizer, Honeywell and the Nestlé Institute of Health Sciences, enhancing her deep sector insight and commercial acumen.

Relevant experience

A global pharmaceutical company in relation to various licence and supply arrangements for the commercialisation of pharmaceuticals in a number of territories.
Bayer Crop Science in relation to the sale of its Norwich based manufacturing business (now Briar Chemicals Limited) to the Aurelius Group.
Chugui Pharma Marketing in relation to the license of exclusive commercialisation rights to Swiss based Helsiun group’s innovative ghrelin receptor agonist, anamorelin, for the three major European pharmaceutical markets.
On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell. We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
Advising in relation to responses to the UK Government’s ventilator challenge and call for PPE during the COVID-19 pandemic, including in respect of negotiations with the Cabinet Office.
hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
Medtronic on the distribution agreement with Tissuemed for Medtronic to be appointed as exclusive distributor of Obex NeuroFilm™ Cerebrospinal Fluid Barrier in markets outside the US.
Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed

Publications

June 2025 - Digital Healthcare Practice Guide, Chambers and Partners.
Bioscience Law Review

Memberships & Roles

ABPI
ABHI
Biotech Industry Association
Tech UK - Data Analytics and AI Leadership Committee
AI and Genomics Advisory Committee

Education

2006 - Legal Practice Course, BPP, London
2005 - Graduate Diploma in Law, BPP, London
2004 - BSc Biology with a Year in Europe, Imperial College, London

Hannah Curtis is a Partner in the Technology & Media Team and a member of the firm’s Technology, Media & Telecoms Sector Group. Hannah advises across sectors on a broad range of transactions.

With nearly twenty years’ legal experience, she specialises in high value, cross-border, IP-rich transactions and commercial agreements, including licensing, R&D, manufacturing, sales and distribution, collaborations, alliances and joint ventures. During her time with the firm, Hannah has been seconded to the Wellcome Trust, Pfizer, Honeywell and the Nestlé Institute of Health Sciences, enhancing her deep sector insight and commercial acumen.

Relevant experience

A global pharmaceutical company in relation to various licence and supply arrangements for the commercialisation of pharmaceuticals in a number of territories.
Bayer Crop Science in relation to the sale of its Norwich based manufacturing business (now Briar Chemicals Limited) to the Aurelius Group.
Chugui Pharma Marketing in relation to the license of exclusive commercialisation rights to Swiss based Helsiun group’s innovative ghrelin receptor agonist, anamorelin, for the three major European pharmaceutical markets.
On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell. We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
Advising in relation to responses to the UK Government’s ventilator challenge and call for PPE during the COVID-19 pandemic, including in respect of negotiations with the Cabinet Office.
hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
Medtronic on the distribution agreement with Tissuemed for Medtronic to be appointed as exclusive distributor of Obex NeuroFilm™ Cerebrospinal Fluid Barrier in markets outside the US.
Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.

Education

2006 - Legal Practice Course, BPP, London
2005 - Graduate Diploma in Law, BPP, London
2004 - BSc Biology with a Year in Europe, Imperial College, London

Hannah Curtis is a partner in the Technology & Media Team and a member of the firm’s Commercial Practice Group.

With nearly twenty years’ legal experience, she Hannah advises across sectors on a broad range of transactions, specialising in high value, cross-border, IP-rich transactions and commercial agreements, including licensing, R&D, manufacturing, sales and distribution, collaborations, alliances and joint ventures. During her time with the firm, Hannah has been seconded to the Wellcome Trust, Pfizer, Honeywell and the Nestlé Institute of Health Sciences, enhancing her deep sector insight and commercial acumen.

Relevant experience

A global pharmaceutical company in relation to various licence and supply arrangements for the commercialisation of pharmaceuticals in a number of territories.
Bayer Crop Science in relation to the sale of its Norwich based manufacturing business (now Briar Chemicals Limited) to the Aurelius Group.
Chugui Pharma Marketing in relation to the license of exclusive commercialisation rights to Swiss based Helsiun group’s innovative ghrelin receptor agonist, anamorelin, for the three major European pharmaceutical markets.
On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell. We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
Advising in relation to responses to the UK Government’s ventilator challenge and call for PPE during the COVID-19 pandemic, including in respect of negotiations with the Cabinet Office.
hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
Medtronic on the distribution agreement with Tissuemed for Medtronic to be appointed as exclusive distributor of Obex NeuroFilm™ Cerebrospinal Fluid Barrier in markets outside the US.
Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.

Education

2006 - Legal Practice Course, BPP, London
2005 - Graduate Diploma in Law, BPP, London
2004 - BSc Biology with a Year in Europe, Imperial College, London

Practice Areas

Commercial ESG Life Sciences Regulatory

sectors

Life Sciences & Healthcare TMT - Technology, Media & Telecommunications Consumer Products

Insights

Global Reach

UK Pay Gap Report 2024

Insights

Global Reach

UK Pay Gap Report 2024

Select your region

Hannah Curtis

Languages

Social media

Relevant experience

Publications

Memberships & Roles

Education

Relevant experience

Education

Relevant experience

Education

Practice Areas

sectors

Insights by Hannah